Sector Gamma AS Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sector Gamma AS lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,000 shares of the medical equipment provider’s stock after selling 712 shares during the quarter. Sector Gamma AS’s holdings in Lantheus were worth $2,440,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Signaturefd LLC grew its stake in Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 116 shares during the last quarter. Hughes Financial Services LLC purchased a new stake in Lantheus during the 1st quarter valued at about $81,000. UMB Bank n.a. grew its stake in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 381 shares during the last quarter. Blue Trust Inc. grew its stake in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 633 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Lantheus by 29.3% in the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after buying an additional 298 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 26,066 shares of the company’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on LNTH shares. JMP Securities decreased their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. William Blair reissued a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. B. Riley decreased their price objective on Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a report on Monday, June 23rd. Wall Street Zen raised Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. Finally, Mizuho decreased their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $105.50.

Lantheus Stock Performance

NASDAQ LNTH opened at $54.47 on Friday. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of 14.49 and a beta of 0.14. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $118.21. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average of $74.38 and a 200 day moving average of $85.74.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. The business’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.80 EPS. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.